These results suggest that targeting METTL1 alone or in combination with immune checkpoint inhibitors holds great potential for developing effective therapeutic strategies, particularly for patients with castration-resistant prostate cancer who have limited treatment options. The gene discussed is METTL1; the disease is prostate cancer.